In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes. (2022)
Attributed to:
Randomised trials in cardiovascular and metabolic disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.7326/j22-0029
PubMed Identifier: 35500259
Publication URI: http://europepmc.org/abstract/MED/35500259
Type: Journal Article/Review
Volume: 175
Parent Publication: Annals of internal medicine
Issue: 5
ISSN: 0003-4819